Treatment News : HIV Medication Increases Immunity to KS Virus

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » September 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


September 7, 2010

HIV Medication Increases Immunity to KS Virus

Starting antiretroviral (ARV) therapy significantly increases a person’s immune responses to the virus that causes Kaposi’s sarcoma (KS), an AIDS-defining cancer. What’s more, these data, which were published in the September 10 issue of AIDS, show that a person’s KS antibody responses can be restored even in people who wait to start ARVs until their CD4 count is low.

In the early years of the AIDS epidemic, KS was one of the most common forms of cancer in people living with HIV. It was also one of the opportunistic infections that most dramatically responded to the introduction of potent combination ARV therapy in 1996. Not only did ARVs send KS rates plummeting, but they also caused the cancer to disappear in significant numbers of people who already had KS. While ARV therapy’s ability to fight this cancer has been well established, scientists are still working to understand how ARVs accomplish this feat.

To shed additional light on this subject, Sheena Sullivan, PhD, from the University of California at Los Angeles, and her colleagues analyzed blood samples from 272 HIV-positive men who have sex with men (MSM) who started ARV therapy between 1996 and 2004. Blood samples were taken roughly one month before the men started ARV therapy and 24 months later. Twenty-two of the men had been diagnosed with KS before starting treatment.

Sullivan and her colleagues tested the blood samples for two types of antibodies—latent and lytic—to the virus that causes KS, the human herpes virus 8 (HHV8). While both latent and lytic antibodies bind to HHV8, they do so at different parts of the virus’s life cycle. The team also directly measured levels of HHV8 in the blood.

Seventeen people—seven with KS and 10 without—had measurable HHV8 levels at the time they started ARVs. After 24 months of treatment, 16 of them no longer had measurable HHV8 levels. While seven additional people did develop measurable HHV8 after starting treatment, the level of virus in these individuals was very low.

The most dramatic effect of ARV therapy on KS immunity was found in the development of antibody responses to HHV8. Sullivan’s team found that the number of people with HHV8 antibody responses significantly increased after taking ARVs. This effect was most pronounced, however, among those who had KS at the start of the study: They were 22 times more likely to develop an anti-KS antibody response after 24 months of HIV treatment than those who did not have KS before starting treatment.

In terms of those people who tested positive for the HHV8 antibodies only after going on HIV treatment, the authors comment that this was likely not due to people becoming newly infected with HHV8. Rather, people probably did have HHV8 antibodies, but their immune systems were so damaged that they were unable to produce enough antibodies for the test to recognize them.

Intriguingly, Sullivan and her colleagues found that low CD4s at the beginning of HIV treatment were no barrier to developing a strengthened immune response to KS. Older age and higher CD8 levels did, however, diminish the likelihood of a person developing an improved antibody response to KS—a finding similar to other studies.

“Increases in [antibody] immune response may partly explain…the dramatic protection against [KS] offered by [ARV therapy], even when it is initiated at very low CD4 cell counts,” the authors concluded. “[These results] may also apply to [antibody] responses to other viral infections among people with HIV.”

Search: Kaposi's sarcoma, KS, human herpes virus 8, HHV8, antibodies, lytic antibodies, latent antibodies, Sheena Sullivan

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.